Neptune Medical has received FDA clearance for its Triton 1 Robotic Endoscopy System, designed to perform diagnostic and therapeutic procedures throughout the colon. The robotic system is intended to provide greater stability and control during colonoscopy and can be used for screening, surveillance, diagnosis and more complex procedures such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD).
The clearance follows Neptune’s 50-patient first-in-human CARE 1 study, presented at DDW 2026. The company reported 100% cecal intubation, no adverse events and a 54.2% adenoma detection rate, compared with a cited industry threshold of 35%. The system also produced a 67% lower average ergonomic burden for endoscopists and required no patient repositioning, abdominal pressure or conversion to manual colonoscopy during the study.